Esophagectomy With Three-Field Versus Two-Field Lymphadenectomy for Middle and Lower Thoracic Esophageal Cancer: Long-Term Outcomes of a Randomized Clinical Trial
Bin Li,Yawei Zhang,Longsheng Miao,Longfei Ma,Xiaoyang Luo,Yiliang Zhang,Ting Ye,Hecheng Li,Jie Zhang,Yuan Li,Kuaile Zhao,Min Fan,Zhengfei Zhu,Jialei Wang,Jie Xu,Youjia Deng,Qiong Lu,Hang Li,Yang Zhang,Yunjian Pan,Shilei Liu,Longlong Shao,Yihua Sun,Jiaqing Xiang,Hong Hu,Haiquan Chen
DOI: https://doi.org/10.1016/j.jtho.2020.10.157
IF: 20.121
2021-02-01
Journal of Thoracic Oncology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Introduction</h3><p>The optimal extent of lymphadenectomy during esophagectomy remains unclear. In this trial, we aim to clarify whether three-field (cervical-thoracic-abdominal) lymphadenectomy improved patient survival over two-field (thoracic-abdominal) lymphadenectomy for esophageal cancer.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Between March 2013 to November 2016, 400 patients with middle and lower thoracic esophageal cancer were included, and randomly assigned to undergo esophagectomy with either three- or two-field lymphadenectomy at a 1:1 ratio. Analyses were done according to the intention-to-treat principle. The primary endpoint was overall survival (OS), calculated from the date of randomization to the date of death from any cause.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>emographic characteristics were similar in the two arms. The median follow-up time was 55 months (95% confidence interval [CI], 52-58). Overall survival were comparable between the two arms (hazard ratio [HR], 1.019, 95% CI, 0.727-1.428, <em>P</em>=0.912) , as well as the disease-free survival (DFS) (HR, 0.868, 95% CI, 0.636-1.184, <em>P</em>=0.371) .The cumulative 5-year OS was 63% in the three-field arm, as compared with 63% in the two-field arm; 5-year DFS were 59% and 53%, respectively. Based on whether the patients had mediastinal/abdominal lymph nodes metastasis or not, overall survivals were also comparable between the two arms. In this cohort, only advanced tumor stage (pTNM stage III-IV) was identified as the risk factor associated with reduced OS (HR, 3.330, 95% CI, 2.140-5.183, <em>P</em><0.001).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>For patients with middle and lower thoracic esophageal cancer, there was no improvement in OS or DFS after esophagectomy with three-field lymphadenectomy over two-field lymphadenectomy.</p>
oncology,respiratory system